通过靶向肿瘤相关巨噬细胞的嵌合受体工程化溶瘤病毒重振内源性抗肿瘤免疫
Rejuvenating endogenous antitumor immunity via a chimeric receptor-engineered oncolytic virus targeting tumor-associated macrophages.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CRISPR/Cas9 在临床癌症研究中的应用现状：机遇与挑战
英文原题：Current Status of CRISPR/Cas9 Application in Clinical Cancer Research: Opportunities and Challenges.
查看英文原题
Current Status of CRISPR/Cas9 Application in Clinical Cancer Research: Opportunities and Challenges.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
癌症不仅涉及多种遗传改变，也涉及驱动恶性细胞增殖并导致化疗耐药的表观遗传改变。纠正或清除这些突变对于抗癌具有巨大潜力。近年来，CRISPR-Cas9基因组编辑技术因效率高、可行性强，已被广泛用于癌症治疗研究。多项研究在细胞和动物癌症模型中利用CRISPR-Cas9编辑癌细胞基因组DNA，并显示其有望增强抗癌治疗方案。此外，CRISPR-Cas9还可用于纠正致癌突变、发现抗癌药物，以及工程化改造免疫细胞和溶瘤病毒以开展癌症免疫治疗。本文讨论将CRISPR-Cas9治疗方法转化用于临床所面临的挑战和机遇，并提出CRISPR-Cas9系统未来癌症治疗的潜在发展方向。
展开英文摘要原文
Cancer is considered by not only multiple genetic but also epigenetic amendments that drive malignant cell propagation and consult chemo-resistance. The ability to correct or ablate such mutations holds enormous promise for battling cancer.
Recently, because of its great efficiency and feasibility, the CRISPR-Cas9 advanced genome editing technique has been extensively considered for therapeutic investigations of cancers. Several studies have used the CRISPR-Cas9 technique for editing cancer cell genomic DNA in cells and animal cancer models and have shown therapeutic potential in intensifying anti-cancer protocols.
Moreover, CRISPR-Cas9 may be used to correct oncogenic mutations, discover anticancer drugs, and engineer immune cells and oncolytic viruses for immunotherapeutic treatment of cancer.
We herein discuss the challenges and opportunities for translating therapeutic methods with CRISPR-Cas9 for clinical use and suggest potential directions of the CRISPR-Cas9 system for future cancer therapy.
论文信息
- 作者
- Rafii S、Tashkandi E、Bukhari N、Al-Shamsi HO
- 第一作者单位
- Department of Oncology, Saudi German Hospital, Dubai P.O. Box 391093, United Arab Emirates.
- 通讯作者单位
- Emirates Oncology Society, Dubai P.O. Box 6600, United Arab Emirates.
- 文献类型
- 综述
- 期刊
- Cancers2022 Feb 14
- 原文标识
- PubMed 35205694 · DOI 10.3390/cancers14040947
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →